MSI2 and cancer: Smarcd3KO-KPf/fC tumors (Supplementary Fig. 2d, e) showed a trend towards reduced EpCAM+ tumor cell content, and a 2.5-fold reduction in EpCAM+MSI2+ cancer stem cells at midpoint (7–8 weeks) (Fig. 2b, Supplementary Fig. 2f).